Author of

• 10984

  +

  P1.22 - Poster Session 1 - Epidemiology, Etiology (ID 166)

  • Event: WCLC 2013
  • Type: Poster Session
  • Track: Prevention & Epidemiology
  • Presentations: 1
  • Moderators:
  • Coordinates: 10/28/2013, 09:30 - 16:30, Exhibit Hall, Ground Level

  • 10990

    +

    P1.22-006 - The impact of sex hormone-binding globulin levels on thromboembolic events at cancer patients with adenocarcinoma (ID 2410)

    09:30 - 09:30  |  Author(s): M. Bozkurt
    • Abstract

    Background
    Thromboembolic events (TE) are common complication of cancer, may lead to mortality and detoriate quality of life. The most common malignancies associated with TE’s are adenocarcinomas and the mechanism needs to be elucidated.Several studies suggest that increased risk of TE’s with hormonal contraceptives is mediated through the sex hormone-binding globulin levels (SHBG). The aim of this study is to investigate if the SHBG level is associated with TE’s in cancer patients with adenocarcinoma.

    Methods
    We compared the SHBG levels in 45 patients with TE and 23 patients without TE, all of them cancer with adenocarcinoma histology. A p value of less than 0.05 was considered statistically significant.

    Results
    Sixty eight patients, aged between 37-80, are evaluated. Thirty five women. There was no statistical significant relationship for age and gender between TE and non-TE groups. AT TE group, 20 (44%) had distal lower extremity (DLE) deep venous thrombosis (DVT), 17 (38%) had PE and the rest includes 4 central/proximal DVT (9%), 4 central venous catheter-related DVT (9%). Frequencies of histopathology for TE and non-TE group were; colorectal cancer 20 (30 %), gastric cancer 13 (20 %), pancreatic cancer 11(16%), breast 10 (%14), Lung 6 (9 %), and other (prostatic 3, hepatobiliary 2, unknown primary 2 and ovarian 1) 8 (%11). There was no difference between SHBG levels with TE group (mean±SD; 59±41) and non-TE group (60±49)( student’s t test; p=0.98).

    Conclusion
    SHBG levels do not play any role in the mechanism of cancer- related thrombosis in patients with adenocarcinoma.